BR100 Decreased By (-0.4%)
BR30 Decreased By (-0.65%)
KSE100 Decreased By (-0.29%)
KSE30 Decreased By (-0.22%)
AGHA 6.56 Decreased By ▼ -0.11 (-1.65%)
BECO 4.40 Increased By ▲ 0.05 (1.15%)
BML 55.89 Decreased By ▼ -0.28 (-0.5%)
BOP 30.05 Decreased By ▼ -0.07 (-0.23%)
CNERGY 12.75 Decreased By ▼ -0.23 (-1.77%)
CSIL 5.21 Decreased By ▼ -0.10 (-1.88%)
FCCL 51.00 Decreased By ▼ -0.65 (-1.26%)
FFL 14.43 Decreased By ▼ -0.06 (-0.41%)
FNEL 1.22 Increased By ▲ 0.01 (0.83%)
KEL 5.97 Decreased By ▼ -0.09 (-1.49%)
KOSM 5.58 Decreased By ▼ -0.26 (-4.45%)
LOTCHEM 26.15 Decreased By ▼ -0.02 (-0.08%)
MLCF 90.33 Decreased By ▼ -0.90 (-0.99%)
NBP 161.45 Decreased By ▼ -2.74 (-1.67%)
NCPL 52.55 Decreased By ▼ -0.63 (-1.18%)
NPL 57.98 Decreased By ▼ -1.14 (-1.93%)
OGDC 315.40 Increased By ▲ 2.01 (0.64%)
PACE 9.70 Decreased By ▼ -0.07 (-0.72%)
PAEL 34.73 Decreased By ▼ -0.51 (-1.45%)
PIBTL 14.23 Decreased By ▼ -0.48 (-3.26%)
PPL 221.00 Decreased By ▼ -0.36 (-0.16%)
PRL 90.89 Decreased By ▼ -0.33 (-0.36%)
PTC 59.25 Increased By ▲ 0.06 (0.1%)
SSGC 23.39 Increased By ▲ 0.09 (0.39%)
TBL 8.65 Decreased By ▼ -0.10 (-1.14%)
TELE 7.40 Decreased By ▼ -0.21 (-2.76%)
TPL 21.00 Decreased By ▼ -1.03 (-4.68%)
TPLP 12.02 Decreased By ▼ -0.54 (-4.3%)
TREET 21.33 Decreased By ▼ -0.40 (-1.84%)
TRG 54.35 Decreased By ▼ -1.44 (-2.58%)
Business & Finance

Moderna plans trial of altered COVID-19 vaccine booster to address South Africa variant

  • The company said the vaccine did not see any impact from the U.K. variant - which has been shown to be more transmissible - in the tests.
  • The company said it plans to publish data from its tests against the South African and U.K. variants on the website.
Published Updated
By

Moderna plans trial of altered COVID-19 vaccine booster to address South Africa variant

Moderna said on Monday it plans to start clinical trials of an altered booster version of its COVID-19 vaccine aimed at the South African variant after tests showed its authorised vaccine may produce a diminished antibody response.

It will also test an additional booster shot of its authorised vaccine in trials to see if it boosts antibody reaction against the South Africa variant. The current regimen is for two shots four weeks apart.

The company said in a press release that it was being cautious and that the two-dose regimen of the vaccine was still expected to be protective against the South African and other variants detected to date.

The company said the vaccine did not see any impact from the U.K. variant - which has been shown to be more transmissible - in the tests.

The company said it plans to publish data from its tests against the South African and U.K. variants on the website bioRxiv.

Comments

Comments are closed for this article.